Levothyroxine Oral Solution TIROSINT Recalled Due to Subpotency
IBSA PHARMA is recalling TIROSINT (levothyroxine sodium) oral solution due to subpotency in specific batches. The affected product may contain less active ingredient than labeled.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II recall for a prescription thyroid medication with subpotency—a risk-of-harm condition affecting medication efficacy. Although no illnesses have been reported, patients on thyroid hormone replacement therapy face risk of inadequate treatment.
Plain-English summary
IBSA Pharma Inc. is recalling TIROSINT (levothyroxine sodium) oral solution in response to a subpotency issue identified in certain batches. The affected product is a prescription thyroid hormone replacement medication supplied as an oral solution at 37.5 micrograms per milliliter.
The recall affects specifically two lots: Lot #220552 (expiration 11/2023) and Lot #221055 (expiration 04/2024). These batches contain less active ingredient than the labeled amount, meaning patients may receive a subtherapeutic dose.
The product was distributed nationwide throughout the United States. IBSA Pharma initiated this voluntary recall on January 30, 2023, and the FDA classified it as a Class II recall on April 4, 2023. The recall was terminated on October 31, 2023.
Patients should not stop taking their thyroid medication without consulting their healthcare provider. Those with prescriptions for affected lots should contact their pharmacy or healthcare provider for guidance on obtaining a replacement product with the correct potency.
The recalled product
- Product
- TIROSINT (LEVOTHYROXINE SODIUM)
- Brand
- TIROSINT
- Manufacturer
- IBSA PHARMA INC
- Category
- Drug
- Hazard
- subpotency
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 220552
- Exp. 11/2023
- 221055
- Exp. 04/2024.
UPCs (15)
- 0371858011754
- 0371858013055
- 0371858012553
- 0371858011556
- 0371858015554
- 0371858013550
- 0371858015059
- 0371858014052
- 0371858016056
- 0371858014557
- 0371858010559
- 0371858011358
- 0371858011259
- 0371858011051
- 0371858012058
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TIROSINT
- ModerateTIROSINT Levothyroxine Oral Solution Recalled for Subpotent Drug Content
FDA (Drugs) · 2023-03-01
- HighLevothyroxine sodium oral solution recalled due to subpotency
FDA (Drugs) · 2023-03-01
- HighPrescription drug TIROSINT levothyroxine recalled for subpotent formulation
FDA (Drugs) · 2023-03-01
- HighFDA Recalls TIROSINT Levothyroxine Sodium Oral Solution for Subpotency
FDA (Drugs) · 2023-03-01
- ModerateTIROSINT levothyroxine sodium oral solution recalled for subpotency nationwide
FDA (Drugs) · 2023-03-01
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- HighLacosamide 100mg Tablets Recalled Due to Foreign Tablet Contamination
FDA (Drugs) · 2026-07-01
- ModerateCorlanor Ivabradine Tablets Recalled for Foreign Substance Contamination
FDA (Drugs) · 2026-07-01